Literature DB >> 16054573

Antiemetic guidelines: are they being used?

Rolf Kaiser1.   

Abstract

Evidence-based guidelines are regarded as therapeutic standards for many medical interventions. However, implementation of such recommendations seems to be rather difficult. An international antiemetic guideline for the treatment of patients undergoing chemotherapy was issued by the Multinational Association of Supportive Care in Cancer in 1997 and has been in use ever since. However, for many reasons, the guideline has not been followed completely, despite the fact that if antiemetics are used in accordance with guidelines, efficacy is similar to that achieved in randomised controlled trials. Structural difficulties, patients characteristics, and other barriers, such as the individual acceptance of guidelines and education of physicians and nurses, could be crucial factors for successful implementation. Thus, better adherence to antiemetic guidelines can only be achieved through a complex and long-term process, consisting of efficient education, training, and monitoring of all individuals involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054573     DOI: 10.1016/S1470-2045(05)70284-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  18 in total

1.  Lifting symptom burden--how far off the ground are we?

Authors:  Mellar P Davis; Jordanka Kirkova
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

2.  Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Authors:  Florence Van Ryckeghem
Journal:  J Transl Int Med       Date:  2016-04-14

3.  Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.

Authors:  Ayako Okuyama; Fumiaki Nakamura; Takahiro Higashi
Journal:  Support Care Cancer       Date:  2014-02-14       Impact factor: 3.603

4.  Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  Henning Burmeister; Stefan Aebi; Cristina Studer; Martin F Fey; Oliver Gautschi
Journal:  Support Care Cancer       Date:  2011-01-14       Impact factor: 3.603

5.  Antimicrobial prescribing in the USA for adult acute pharyngitis in relation to treatment guidelines.

Authors:  Steven Y Hong; Ying Taur; Michael R Jordan; Christine Wanke
Journal:  J Eval Clin Pract       Date:  2010-06-25       Impact factor: 2.431

6.  Pattern of prophylaxis administration for chemotherapy-induced nausea and vomiting: an analysis of city-based health insurance data.

Authors:  Fumiaki Nakamura; Takahiro Higashi
Journal:  Int J Clin Oncol       Date:  2012-09-27       Impact factor: 3.402

Review 7.  Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

Authors:  Matti Aapro; Alexandra Carides; Bernardo L Rapoport; Hans-Joachim Schmoll; Li Zhang; David Warr
Journal:  Oncologist       Date:  2015-03-20

Review 8.  Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.

Authors:  Vicky Tc Chan; Winnie Yeo
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-11-14

9.  Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.

Authors:  Sonja Koch; Axel Wein; Jürgen Siebler; Frank Boxberger; Markus F Neurath; Hanns-Detlev Harich; Werner Hohenberger; Frank Dörje
Journal:  Support Care Cancer       Date:  2013-04-09       Impact factor: 3.603

10.  Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.

Authors:  Paul J Hesketh; Jerry Younger; Pedro Sanz-Altamira; Melissa Hayden; Julie Bushey; Brian Trainor; Michael Krentzin; Peter Nowd; Konstantinos Arnaoutakis; Ann M Hesketh
Journal:  Support Care Cancer       Date:  2008-12-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.